利德曼拟17.33亿收购先声祥瑞70%股份 切入生物制品行业推进“双主业”转型

Core Viewpoint - Lide Man plans to seek new growth through an acquisition, aiming to transform the company by acquiring 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. for 1.733 billion yuan [1] Group 1: Acquisition Details - The acquisition will allow Lide Man to enter the bioproducts sector, establishing a dual business model of "bioproducts + in vitro diagnostics" [1] - The transaction has a high premium rate, with Xiansheng Xiangrui's assessed equity value at 2.674 billion yuan, representing a 162.23% increase over its book value of 1.02 billion yuan [2] - Xiansheng Xiangrui has made clear performance commitments, with net profits for 2025, 2026, and 2027 expected to be no less than 166 million yuan, 186 million yuan, and 208 million yuan respectively, totaling at least 558 million yuan over three years [2] Group 2: Financial Performance and Strategic Importance - Xiansheng Xiangrui has shown stable financial performance, with revenues of 653 million yuan, 582 million yuan, and 228 million yuan for 2023, 2024, and the first seven months of 2025 respectively [2] - Lide Man's acquisition is a crucial transformation step due to its declining performance, with a revenue drop of 19.79% in 2024 and a net loss of approximately 75.1 million yuan [3] - The acquisition is expected to help Lide Man quickly penetrate the high-barrier bioproducts industry, reducing the time for product development and market channel establishment [3] Group 3: Financial Pressure and Future Outlook - Lide Man faces financial pressure, with only 618 million yuan in cash available against the 1.733 billion yuan acquisition cost [4] - The company plans to fund the acquisition through its own and raised funds, but failure to secure sufficient funds could jeopardize the transaction [4] - If the acquisition is successful, Lide Man's performance and financial condition are expected to improve, benefiting shareholders, but the success of the transformation will depend on future funding and the fulfillment of performance commitments by Xiansheng Xiangrui [4]